Nuance Pharma Announces Approval of Ohtuvayre™ (ensifentrine) in Macau SAR, China
Nuance Pharma ("Nuance") announced that the Pharmaceutical Administration Bureau Macau approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) ...
Using genetics to identify individuals with undiagnosed chronic obstructive pulmonary disease
In a recent study, Mass General Brigham researchers demonstrated that through low-cost genetic samples that can be obtained from a cheek swab or blood test, they can improve identification of people ...
Medindia1d
Areteia's Dexpramipexole: A New Oral Treatment for Asthma
Areteia Therapeutics introduces dexpramipexole, a novel oral drug in Phase 3 trials for asthma and COPD, aiming for approval ...
Pharmabiz2d
China NMPA clears Harbour BioMed’s IND application for HBM9378/SKB378 for chronic obstructive pulmonary disease treatment
Cambridge, Massachusetts Thursday, February 6, 2025, 13:00 Hrs [IST] ...
Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and ...
Hosted on MSN4d
COPD Flare-up? Here's How to Breathe Easier and When to Call a Doctor
Chronic obstructive pulmonary disease (COPD), a condition that affects more than 14 million U.S. adults, is marked by damage ...
Fisher & Paykel’s Long-Term Trajectory Is Intact
Fisher & Paykel is well-positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital division is ...
TruNeb Announces Upgrades to Portable Nebulizer As Part of Efforts to Advance Respiratory Care in 2025
Upgrades aim to improve asthma relief and COPD treatment with advanced technology.United States, January 31, 2025 -- TruNeb ...